Enbrel is an extreme example of unintended marketing exclusivity (30 years), a result of our flawed drug patent system. The implementation of the negotiated maximum fair price (MFP) in January 2026 for the Medicare population will at least be a tentative step to obtaining better value for this individual biologic. We reported back in August … Continue reading Does the Colorado Decision on Enbrel Represent a New Threat to Biosimilar Development?